Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance.

Joosten SPJ, Mizutani T, Spaargaren M, Clevers H, Pals ST.

Gastroenterology. 2019 Oct;157(4):1153-1155.e1. doi: 10.1053/j.gastro.2019.06.029. Epub 2019 Jun 27. No abstract available.

PMID:
31255653
2.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Beerenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2019 May 23. pii: haematol.2018.214122. doi: 10.3324/haematol.2018.214122. [Epub ahead of print]

3.

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, De Raeve H, De Smedt E, Vlummens P, Szablewski V, Devin J, Faict S, De Veirman K, Menu E, Offner F, Spaargaren M, Moreaux J, Vanderkerken K, Van Valckenborgh E, De Bruyne E.

Br J Cancer. 2019 Jun;120(12):1137-1146. doi: 10.1038/s41416-019-0471-0. Epub 2019 May 15.

PMID:
31089208
4.

Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.

van Andel H, Kocemba KA, Spaargaren M, Pals ST.

Leukemia. 2019 May;33(5):1063-1075. doi: 10.1038/s41375-019-0404-1. Epub 2019 Feb 15. Review.

5.

Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.

Ren Z, van Andel H, de Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, Spaargaren M, Pals ST.

Blood. 2018 Mar 1;131(9):982-994. doi: 10.1182/blood-2017-07-797050. Epub 2017 Dec 6.

PMID:
29212806
6.

Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.

Singh SP, Pillai SY, de Bruijn MJW, Stadhouders R, Corneth OBJ, van den Ham HJ, Muggen A, van IJcken W, Slinger E, Kuil A, Spaargaren M, Kater AP, Langerak AW, Hendriks RW.

Oncotarget. 2017 May 26;8(42):71981-71995. doi: 10.18632/oncotarget.18234. eCollection 2017 Sep 22.

7.

MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms.

Joosten SPJ, Zeilstra J, van Andel H, Mijnals RC, Zaunbrecher J, Duivenvoorden AAM, van de Wetering M, Clevers H, Spaargaren M, Pals ST.

Gastroenterology. 2017 Oct;153(4):1040-1053.e4. doi: 10.1053/j.gastro.2017.07.008. Epub 2017 Jul 14.

PMID:
28716720
8.

Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.

van Andel H, Ren Z, Koopmans I, Joosten SP, Kocemba KA, de Lau W, Kersten MJ, de Bruin AM, Guikema JE, Clevers H, Spaargaren M, Pals ST.

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):376-381. doi: 10.1073/pnas.1618650114. Epub 2016 Dec 27.

9.

The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.

van Keimpema M, Grüneberg LJ, Schilder-Tol EJ, Oud ME, Beuling EA, Hensbergen PJ, de Jong J, Pals ST, Spaargaren M.

Haematologica. 2017 Mar;102(3):573-583. doi: 10.3324/haematol.2016.156455. Epub 2016 Dec 1.

10.

Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.

Pals ST, Kersten MJ, Spaargaren M.

Best Pract Res Clin Haematol. 2016 Jun;29(2):161-168. doi: 10.1016/j.beha.2016.08.019. Epub 2016 Sep 7. Review.

PMID:
27825462
11.

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.

van Andel H, Kocemba KA, de Haan-Kramer A, Mellink CH, Piwowar M, Broijl A, van Duin M, Sonneveld P, Maurice MM, Kersten MJ, Spaargaren M, Pals ST.

Oncogene. 2017 Apr;36(15):2105-2115. doi: 10.1038/onc.2016.368. Epub 2016 Oct 24.

PMID:
27775078
12.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
13.

Ibrutinib for AML? Check CD117 (KIT)!

Spaargaren M.

Lancet Haematol. 2015 May;2(5):e180-1. doi: 10.1016/S2352-3026(15)00069-1. Epub 2015 Apr 14. No abstract available.

PMID:
26688091
14.

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

de Rooij MF, Kuil A, Kraan W, Kersten MJ, Treon SP, Pals ST, Spaargaren M.

Haematologica. 2016 Mar;101(3):e111-5. doi: 10.3324/haematol.2015.137265. Epub 2015 Dec 3. No abstract available.

15.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4. Erratum in: Leukemia. 2016 Sep;30(9):1963.

PMID:
26338274
16.

The forkhead transcription factor FOXP1 represses human plasma cell differentiation.

van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, van Zelm MC, Coffer P, Pals ST, Spaargaren M.

Blood. 2015 Oct 29;126(18):2098-109. doi: 10.1182/blood-2015-02-626176. Epub 2015 Aug 19.

17.

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

de Rooij MF, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M.

Blood. 2015 Apr 2;125(14):2306-9. doi: 10.1182/blood-2014-12-619163. No abstract available.

18.

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.

Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST.

Blood Cancer J. 2014 Dec 12;4:e266. doi: 10.1038/bcj.2014.87. No abstract available.

19.

FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.

van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, Pals ST, Spaargaren M.

Blood. 2014 Nov 27;124(23):3431-40. doi: 10.1182/blood-2014-01-553412. Epub 2014 Sep 29.

20.

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Spaargaren M, de Rooij MF, Kater AP, Eldering E.

Oncogene. 2015 May 7;34(19):2426-36. doi: 10.1038/onc.2014.181. Epub 2014 Jun 23. Review.

PMID:
24954503
21.

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST.

Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20. No abstract available.

PMID:
24253023
22.

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.

Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ, Spaargaren M, Pals ST.

Blood Cancer J. 2013 Sep 6;3:e139. doi: 10.1038/bcj.2013.28.

23.

CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status.

Zeilstra J, Joosten SP, Vermeulen L, Koster J, Medema JP, Versteeg R, Spaargaren M, Pals ST.

PLoS One. 2013 Aug 29;8(8):e72849. doi: 10.1371/journal.pone.0072849. eCollection 2013.

24.

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L.

Blood. 2013 Oct 3;122(14):2412-24. doi: 10.1182/blood-2013-02-482125. Epub 2013 Aug 12.

25.

The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis.

Kocemba KA, van Andel H, de Haan-Kramer A, Mahtouk K, Versteeg R, Kersten MJ, Spaargaren M, Pals ST.

Leukemia. 2013 Aug;27(8):1729-37. doi: 10.1038/leu.2013.76. Epub 2013 Mar 12.

PMID:
23478664
26.

Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma.

Reijmers RM, Spaargaren M, Pals ST.

FEBS J. 2013 May;280(10):2180-93. doi: 10.1111/febs.12180. Epub 2013 Mar 4. Review.

27.

Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling.

Zeilstra J, Joosten SP, van Andel H, Tolg C, Berns A, Snoek M, van de Wetering M, Spaargaren M, Clevers H, Pals ST.

Oncogene. 2014 Jan 30;33(5):665-70. doi: 10.1038/onc.2012.611. Epub 2013 Jan 14.

PMID:
23318432
28.

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations.

Langerak AW, Groenen PJ, Brüggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter GI, Catherwood M, Davi F, Delfau-Larue MH, Diss T, Evans PA, Gameiro P, Garcia Sanz R, Gonzalez D, Grand D, Håkansson A, Hummel M, Liu H, Lombardia L, Macintyre EA, Milner BJ, Montes-Moreno S, Schuuring E, Spaargaren M, Hodges E, van Dongen JJ.

Leukemia. 2012 Oct;26(10):2159-71. doi: 10.1038/leu.2012.246. Epub 2012 Aug 24. Review.

29.

Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.

Kocemba KA, Groen RW, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M, Pals ST.

PLoS One. 2012;7(2):e30359. doi: 10.1371/journal.pone.0030359. Epub 2012 Feb 17.

30.

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M.

Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.

PMID:
22279054
31.

Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation.

Celie JW, Katta KK, Adepu S, Melenhorst WB, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ploeg RJ, Navis G, van der Heide JJ, van Dijk MC, van Goor H, van den Born J.

Kidney Int. 2012 Apr;81(7):651-61. doi: 10.1038/ki.2011.425. Epub 2012 Jan 11.

32.

Lymphoma spread? Target CD47-SIRPα!

Spaargaren M.

Blood. 2011 Nov 3;118(18):4762-4. doi: 10.1182/blood-2011-09-375139. No abstract available.

PMID:
22053171
33.

N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.

Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB, Aalders L, Rozemuller H, Martens AC, Bergsagel PL, Kersten MJ, Pals ST, Spaargaren M.

Haematologica. 2011 Nov;96(11):1653-61. doi: 10.3324/haematol.2010.038133. Epub 2011 Aug 9.

34.

Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.

Reijmers RM, Groen RW, Kuil A, Weijer K, Kimberley FC, Medema JP, van Kuppevelt TH, Li JP, Spaargaren M, Pals ST.

Blood. 2011 Jun 9;117(23):6162-71. doi: 10.1182/blood-2010-12-325522. Epub 2011 Apr 6.

PMID:
21471524
35.

WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer.

Zeilstra J, Joosten SP, Wensveen FM, Dessing MC, Schütze DM, Eldering E, Spaargaren M, Pals ST.

Biochem Biophys Res Commun. 2011 Mar 4;406(1):1-6. doi: 10.1016/j.bbrc.2010.12.070. Epub 2010 Dec 22.

PMID:
21184732
36.

The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.

Mahtouk K, Tjin EP, Spaargaren M, Pals ST.

Biochim Biophys Acta. 2010 Dec;1806(2):208-19. doi: 10.1016/j.bbcan.2010.07.006. Epub 2010 Jul 22. Review.

PMID:
20655987
37.

NH-1,2,3-Triazole-based Inhibitors of the VIM-2 Metallo-β-Lactamase: Synthesis and Structure-Activity Studies.

Weide T, Saldanha SA, Minond D, Spicer TP, Fotsing JR, Spaargaren M, Frère JM, Bebrone C, Sharpless KB, Hodder PS, Fokin VV.

ACS Med Chem Lett. 2010 Jul 8;1(4):150-154.

38.

Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase.

Reijmers RM, Vondenhoff MF, Roozendaal R, Kuil A, Li JP, Spaargaren M, Pals ST, Mebius RE.

J Immunol. 2010 Apr 1;184(7):3656-64. doi: 10.4049/jimmunol.0902200. Epub 2010 Mar 5.

39.

Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.

Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikós T, Martens AC, Spaargaren M, Pals ST.

Blood. 2010 Jan 21;115(3):601-4. doi: 10.1182/blood-2009-02-204396. Epub 2009 Nov 13.

PMID:
19965677
40.

Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

Minond D, Saldanha SA, Subramaniam P, Spaargaren M, Spicer T, Fotsing JR, Weide T, Fokin VV, Sharpless KB, Galleni M, Bebrone C, Lassaux P, Hodder P.

Bioorg Med Chem. 2009 Jul 15;17(14):5027-37. doi: 10.1016/j.bmc.2009.05.070. Epub 2009 Jun 22.

41.

Instant conditional transgenesis in the mouse hematopoietic compartment.

Csikós T, Reijmers RM, Uren AG, Spaargaren M, Pals ST.

J Immunol Methods. 2008 Dec 31;339(2):259-63. doi: 10.1016/j.jim.2008.08.009. Epub 2008 Sep 13.

PMID:
18793641
42.

Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.

Groen RW, Oud ME, Schilder-Tol EJ, Overdijk MB, ten Berge D, Nusse R, Spaargaren M, Pals ST.

Cancer Res. 2008 Sep 1;68(17):6969-77. doi: 10.1158/0008-5472.CAN-08-1322.

43.

Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.

Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST.

Cancer Res. 2008 May 15;68(10):3655-61. doi: 10.1158/0008-5472.CAN-07-2940.

44.

The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells.

de Gorter DJ, Reijmers RM, Beuling EA, Naber HP, Kuil A, Kersten MJ, Pals ST, Spaargaren M.

Blood. 2008 Apr 1;111(7):3364-72. doi: 10.1182/blood-2007-08-106583. Epub 2008 Jan 28.

PMID:
18227351
45.

Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria.

Celie JW, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ter Wee PM, Florquin S, van den Born J.

Am J Physiol Renal Physiol. 2008 Jan;294(1):F253-63. Epub 2007 Nov 21.

46.

Lymphoma dissemination: the other face of lymphocyte homing.

Pals ST, de Gorter DJ, Spaargaren M.

Blood. 2007 Nov 1;110(9):3102-11. Epub 2007 Jul 26. Review.

PMID:
17656647
47.

Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, Pals ST, Spaargaren M.

Immunity. 2007 Jan;26(1):93-104.

48.

The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral.

de Gorter DJ, Vos JC, Pals ST, Spaargaren M.

J Immunol. 2007 Feb 1;178(3):1405-14.

49.

Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936.

Evans PA, Pott Ch, Groenen PJ, Salles G, Davi F, Berger F, Garcia JF, van Krieken JH, Pals S, Kluin P, Schuuring E, Spaargaren M, Boone E, González D, Martinez B, Villuendas R, Gameiro P, Diss TC, Mills K, Morgan GJ, Carter GI, Milner BJ, Pearson D, Hummel M, Jung W, Ott M, Canioni D, Beldjord K, Bastard C, Delfau-Larue MH, van Dongen JJ, Molina TJ, Cabeçadas J.

Leukemia. 2007 Feb;21(2):207-14. Epub 2006 Dec 14.

PMID:
17170731
50.

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.

Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJ, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue MH, Kneba M, van Dongen JJ, Beldjord K, Molina TJ.

Leukemia. 2007 Feb;21(2):215-21. Epub 2006 Dec 14.

PMID:
17170730

Supplemental Content

Loading ...
Support Center